BT7480 (Nectin-4 CD137, TICA)

11/4/21- Trial initiated. 12/14/23- Define the RP2D and dose range and a design of Ph2 trial in 2024. 9/14/24 Initial data (poster) at ESMO '24. 5/1/25- Trial ongoing. 10/30/25:- Plan Ph1 BT7480+nivolumab data presentation at scientific conference in H1 2026. 03/17/26:- Ph1 BT7480+nivolumab data H1 2026; internal development to cease after data; partner sought. 04/30/26:- PR No update.